Haisco Pharmaceutical Group Co., Ltd.

SZSE:002653 Stock Report

Market Cap: CN¥33.7b

Haisco Pharmaceutical Group Past Earnings Performance

Past criteria checks 4/6

Haisco Pharmaceutical Group's earnings have been declining at an average annual rate of -14.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 4.2% per year. Haisco Pharmaceutical Group's return on equity is 9.4%, and it has net margins of 10.5%.

Key information

-14.4%

Earnings growth rate

-14.6%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-4.2%
Return on equity9.4%
Net Margin10.5%
Last Earnings Update30 Jun 2024

Recent past performance updates

Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

Aug 22
Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

Recent updates

Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

Aug 22
Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Jul 25
With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet

Jul 04
Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet

Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Jun 17
Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well

Mar 19
These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well

Risks To Shareholder Returns Are Elevated At These Prices For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Feb 27
Risks To Shareholder Returns Are Elevated At These Prices For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Revenue & Expenses Breakdown

How Haisco Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:002653 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 243,6723851,638522
31 Mar 243,4843581,566509
31 Dec 233,3552951,522517
30 Sep 233,3023751,585512
30 Jun 233,1382821,534477
31 Mar 233,0772801,509453
01 Jan 233,0152771,465448
30 Sep 222,9591731,403425
30 Jun 222,744951,325417
31 Mar 222,607841,256425
01 Jan 222,7733451,331431
30 Sep 212,8665091,355471
30 Jun 213,1547281,444486
31 Mar 213,4697961,626447
31 Dec 203,3306371,585406
30 Sep 203,3265131,707317
30 Jun 203,5204881,790259
31 Mar 203,6875721,875244
31 Dec 193,9374941,973235
30 Sep 194,3294131,887236
30 Jun 194,1054231,837229
31 Mar 193,7883231,630214
31 Dec 183,4273331,511204
30 Sep 182,6243371,320128
30 Jun 182,208247989184
31 Mar 182,0612541,024152
31 Dec 171,856238939119
30 Sep 171,8063351,02296
30 Jun 171,6063411,0200
31 Mar 171,5354448870
31 Dec 161,4364437770
30 Sep 161,3424065960
30 Jun 161,3263955880
31 Mar 161,1473154650
31 Dec 151,2123724520
30 Sep 151,1793724310
30 Jun 151,2334344210
31 Mar 151,2264694300
01 Jan 151,2114514350
30 Sep 141,1105203610
30 Jun 141,0675243240
31 Mar 141,0315202970
31 Dec 139925192870
30 Sep 139985023180

Quality Earnings: 002653 has high quality earnings.

Growing Profit Margin: 002653's current net profit margins (10.5%) are higher than last year (9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002653's earnings have declined by 14.4% per year over the past 5 years.

Accelerating Growth: 002653's earnings growth over the past year (36.3%) exceeds its 5-year average (-14.4% per year).

Earnings vs Industry: 002653 earnings growth over the past year (36.3%) exceeded the Pharmaceuticals industry -0.8%.


Return on Equity

High ROE: 002653's Return on Equity (9.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies